Allergy and Immunology · Longview, WA
NPI
1710973839
Since 2005
Specialty
Allergy and Immunology
Code 207K00000X
Group practices
3
Medicare group memberships
Hospitals
0
Hospital affiliations
1152 Douglas St
Longview, WA, 98632
Phone (360) 940-0880
Groups this clinician bills Medicare through
Medicare paid, 2024
$192K
12,620 services
Medicare patients, 2024
312
Average age 67
Drug cost, 2024
$4.2M
2,797 prescriptions
Company payments, 2025
$4,210
From 27 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sanjeev Jain was code 95165 (treatment - miscellaneous), 7,403 times for 134 patients. In total Sanjeev Jain billed 12,620 services in 34 codes, and Medicare paid $192K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-11-26.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 95165 Treatment - Miscellaneous | Office | 7,403 | 134 | $12.76 | $94K |
| 95004 Test - Miscellaneous | Office | 2,928 | 35 | $3.47 | $10K |
| 95117 Treatment - Miscellaneous | Office | 778 | 108 | $10.66 | $8,292 |
| 99214 Office E&M - Established | Office | 212 | 128 | $88.39 | $19K |
| 96372 Injection Administration | Office | 94 | 17 | $12.23 | $1,150 |
| 99213 Office E&M - Established | Office | 74 | 57 | $70.18 | $5,193 |
| 95115 Treatment - Miscellaneous | Office | 70 | 13 | $8.18 | $572 |
| 99215 Office E&M - Established | Office | 57 | 24 | $115.17 | $6,565 |
| 99204 Office E&M - New | Office | 37 | 37 | $121.51 | $4,496 |
By year: 2022 $276K for 16,622 services; 2023 $200K for 18,997 services; 2024 $192K for 12,620 services.
Medicare prescription drug claims, 2024
In 2024, the drug Sanjeev Jain prescribed most often to Medicare patients was Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter), with 225 prescriptions and refills. In total Sanjeev Jain wrote 2,797 Medicare prescriptions that cost $4.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 225 | 276 | 52 | $175K |
| Montelukast Sodium Generic | 222 | 409 | 59 | $2,183 |
| Xolair Omalizumab | 190 | 194 | 20 | $669K |
| Hydroxyzine Hcl Generic | 151 | 184 | 36 | $3,014 |
| Epinephrine Generic | 122 | 124 | 96 | $29K |
| Azelastine Hcl Generic | 103 | 155 | 42 | $2,804 |
| Cromolyn Sodium Generic | 96 | 110 | 27 | $31K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 92 | 98 | 51 | $2,042 |
| Famotidine Generic | 90 | 125 | 25 | $1,322 |
| Fluticasone Propionate Generic | 65 | 78 | 26 | $841 |
| Ipratropium Bromide Generic | 62 | 112 | 33 | $2,423 |
| Spiriva Respimat Tiotropium Bromide | 56 | 56 | Under 11 | $29K |
| Symbicort Budesonide/Formoterol Fumarate | 55 | 57 | 16 | $13K |
| Azithromycin Generic | 54 | 71 | 24 | $468 |
| Dupixent Syringe Dupilumab | 54 | 54 | Under 11 | $205K |
Brand drugs: 1,171 claims; generic drugs: 1,626 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sanjeev Jain $4,210 ($4,210 in general payments such as food, travel and fees) from 27 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $760.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 27 | $760 |
| GlaxoSmithKline, LLC. GSK | 25 | $567 |
| Novartis Pharmaceuticals Corporation NVS | 21 | $470 |
| CSL Behring CSL.AX | 15 | $460 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 16 | $314 |
| Genzyme Corporation SNY | 8 | $210 |
| Grifols USA, LLC | 30 | $190 |
| Pfizer Inc. PFE | 5 | $159 |
| Regeneron Healthcare Solutions, Inc. REGN | 7 | $137 |
| ARS Pharmaceuticals Operations, Inc. SPRY | 5 | $126 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.